Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An update from Celadon Pharmaceuticals PLC ( (GB:CEL) ) is now available.
Celadon Pharmaceuticals Plc announced a delay in publishing its Annual Report and Accounts, resulting in a suspension of trading on AIM. The company has secured an additional £1.0 million in debt funding and is negotiating a potential £20.0 million investment, contingent on becoming a private company. Operationally, Celadon is addressing regulatory delays in fulfilling a European contract and is set to launch a new product in the UK. The company has expanded its plant-growing capacity and made its first supply to a U.S. customer, indicating growth opportunities in the American market.
More about Celadon Pharmaceuticals PLC
Celadon Pharmaceuticals Plc is a UK-based pharmaceutical company that specializes in the development, production, and sale of cannabis-based medicines. The company focuses on improving the quality of life for chronic pain sufferers and exploring cannabis-based treatments for conditions such as autism. Celadon’s operations include a 100,000 sq. ft EU-GMP approved facility for cultivation and extraction, and it holds a Home Office license for commercial supply. The company also has a clinical trial for cannabis-based treatments for chronic pain and a minority interest in Kingdom Therapeutics, which is developing a cannabinoid medicine for autism.
Average Trading Volume: 185,325
Technical Sentiment Signal: Sell
Current Market Cap: £7.92M
For an in-depth examination of CEL stock, go to TipRanks’ Overview page.